Author

Moloud Ahmadi

Thermo Fisher Scientific (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Assay:multiome· 1

Frequent Co-Authors

Michelle M. KushidaiD· 2 shared Peter B. DirksiD· 2 shared Yongchang Ji· 2 shared Aiden M. Sababi· 1 shared Alexander MarsoniD· 1 shared Alexis TalbotiD· 1 shared Alvin S. HaiD· 1 shared Ayal HendeliD· 1 shared

Activity by Year

2018-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Michelle M. KushidaORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma

Alexis Talbot, K Li, Jae Hyun J. Lee, Shanshan Lang, Chang Liu, Nechama Kalter, Zhongmei Li, Yasaman Mortazavi, Niran Almudhfar, Joseph J. Muldoon, Vincent Allain, William A. Nyberg, Jing-Yi Chung, Charlotte Wang, Zhongxia Qi, , Brian Rudolph Shy

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

bioRxiv · May 5, 2026 · PreprintCancer Biology

Accelerating CAR T cell manufacturing with an automated next-day process

Moloud Ahmadi, Nicholas Putnam, Max Dotson, Danny Hayoun, Jasmine Padilla, Nujhat Fatima, Prajakta Bhanap, Gertrude Nonterah, Xavier de Mollerat du Jeu, Yongchang Ji

This study introduces an automated 24-hour CAR T cell manufacturing process that increases naive/stem-cell like T cells and cytotoxic activity, potentially improving therapy efficacy and patient access.

Current Research in Translational Medicine · Dec 7, 2024Peer-reviewedBioengineering

PRMT5 is required for full-length HTT expression by repressing multiple proximal intronic polyadenylation sites

Mona Alqazzaz, Felipe E. Ciamponi, Jolene Caifeng Ho, Maxim I. Maron, Manisha Yadav, Aiden M. Sababi, Graham Dickson and Hugh MacLeod, Moloud Ahmadi, Garrett Bullivant, Vincent Tano, Sarah R. Langley, María Sánchez‐Osuna, Patty Sachamitr, Michelle M. Kushida, Laura M. Richards, , Panagiotis Prinos

This paper identifies PRMT5 as a regulator of HTT mRNA splicing and alternative polyadenylation, showing that its inhibition reduces full-length HTT protein levels by promoting premature termination and cleavage.

bioRxiv · Mar 14, 2024 · PreprintNeuroscience

The functional genomic circuitry of human glioblastoma stem cells

Graham MacLeod, Danielle A. Bozek, Nishani Rajakulendran, Vernon Monteiro, Moloud Ahmadi, Zachary Steinhart, Michelle M. Kushida, Helen Yu, Fiona J. Coutinho, Ian Restall, Xiaoguang Hao, Traver Hart, H. Artee Luchman, Samuel Weiss, Peter B. Dirks, Stephane Angers

This study uses CRISPR-Cas9 screens in patient-derived glioblastoma stem cells to identify essential genes and pathways for stemness and drug resistance, revealing new therapeutic targets.

bioRxiv · Jun 28, 2018 · PreprintCancer Biology